Blog of Signaling Pathways

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

34 views | Oct 27 2022

Yasir Y Elamin et al. found that poziotinib was active in EGFR exon 20-mutant NSCLC, although this activity was influenced by insertion location. [Read the Full Post]

Low expression of the metabolism-related gene SLC25A21 predicts unfavourable prognosis in patients with acute myeloid leukaemia

63 views | Oct 27 2022

Wenjun Wang et al. thought that a low expression level of SLC25A21 predicted an unfavourable prognosis in patients with AML. [Read the Full Post]

A Protein Kinase D Inhibitor Suppresses AKT on T cells and Antagonizes Cancer Immunotherapy by Anti-PD-1

52 views | Oct 26 2022

Kazuhide Miyamoto et al. thought that PKD was fundamentally required for T-cell reactivation by anti-PD-1, therefore inhibition of PKD was not appropriate for combination therapy with anti-PD-1. [Read the Full Post]

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

37 views | Oct 26 2022

Natalie F Uy et al. summarized recent progress in novel HER2-targeted agents, and projected next steps in advancing treatment for the thousands of patients with HER2 altered NSCLC. [Read the Full Post]

Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction

0 views | Oct 25 2022

Gang Xie et al. suggested the potential value of PRT in managing osteolytic diseased mediated by osteoclasts. [Read the Full Post]

The Role of Syk in Inflammatory Response of Human Abdominal Aortic Aneurysm Tissue

0 views | Oct 25 2022

Ryo Kanamoto et al. found an important role of Syk for IgG-dependent inflammatory response in human AAA. [Read the Full Post]

Expression patterns and therapeutic implications of histone deacetylase-1 across carcinomas: a comprehensive molecular docking and MD simulation study

69 views | Oct 24 2022

Bader Alshehri signified that targeting HDAC1 was a promising therapeutic strategy, and exploring novel therapeutic agents through basic, translational design might lead to their ultimate use in cancer prevention. [Read the Full Post]

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

64 views | Oct 24 2022

Jeffrey S Weber et al. found that combining CPI and mocetinostat had favorable response rates but with high levels of toxicity. [Read the Full Post]

Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients

32 views | Oct 23 2022

Luhong Wang et al. thought that COVID-19 and HCC were closely linked at the molecular level and proposes drugs that might play an important role in HCC patients with COVID-19. [Read the Full Post]

A Dentin Biomimetic Remineralization Material with an Ability to Stabilize Collagen

42 views | Oct 23 2022

Siying Tao et al. indicated that PNG had great potential to combat early dentin caries for future clinical application. [Read the Full Post]

TGF-β1 Promotes Zika Virus Infection in Immortalized Human First-Trimester Trophoblasts via the Smad Pathway

28 views | Oct 22 2022

Quang Duy Trinh et al. found that TGF-β1 promotes the virus infection via the Smad pathway. [Read the Full Post]

Norepinephrine and dopamine contribute to distinct repetitive behaviors induced by novel odorant stress in male and female mice

22 views | Oct 22 2022

Daniel J Lustberg et al. established a simple method for repeated assessment of stress-induced repetitive behaviors in mice. [Read the Full Post]

Norepinephrine and dopamine contribute to distinct repetitive behaviors induced by novel odorant stress in male and female mice

0 views | Oct 22 2022

Daniel J Lustberg et al. established a simple method for repeated assessment of stress-induced repetitive behaviors in mice. [Read the Full Post]

Delta-short consensus repeat 4-decay accelerating factor (DAF: CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis

0 views | Oct 21 2022

Shuji Miyagawa et al. thought that SCR2-4 was required but no relation to its complement regulatory function exists. [Read the Full Post]

Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia

0 views | Oct 21 2022

William F Richter et al. defined alternative proliferation pathways that more directly derived from H3K79me2 loss. [Read the Full Post]

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma

0 views | Oct 20 2022

Cristina Zahonero et al. found that dacomitinib clearly affected receptor signaling in vivo and that its strong antitumoral effect was independent of the presence of mutant receptor isoforms although it could be affected by the PTEN status [Read the Full Post]

Chai-Hu-San-Shen Capsule Ameliorates Ventricular Arrhythmia Through Inhibition of the CaMKII/FKBP12.6/RyR2/Ca2+ Signaling Pathway in Rats with Myocardial Ischemia

47 views | Oct 20 2022

Longqing Chen et al. found that CHSSC might reduce the incidence of ventricular arrhythmias following myocardial ischemia through inhibition of the CaMKII/RyR2/FKBP12.6/Ca2+ signaling pathway. [Read the Full Post]

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway

35 views | Oct 19 2022

Shuhan Liu et al. indicated that KPT-8602 could be used as a novel potential therapeutic agent for the treatment of inflammasome-related diseases such as Parkinson's disease, through the regulation of the NF-κB signaling pathway and the NLRP3 inflammasome. [Read the Full Post]

URMC-099 prophylaxis prevents hippocampal vascular vulnerability and synaptic damage in an orthopedic model of delirium superimposed on dementia

60 views | Oct 19 2022

Patrick Miller-Rhodes et al. linked post-surgical endothelial activation, microglial MafB immunoreactivity, and synapse loss as key substrates for DSD, all of which could be prevented by URMC-099. [Read the Full Post]

Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases

31 views | Oct 18 2022

Su'an Tang et al. provided a background on autoimmune diseases and provided an update on investigational SYK inhibitors. [Read the Full Post]